Results 1 to 10 of about 352,135 (348)

Transcription factor mutations in myelodysplastic/myeloproliferative neoplasms

Haematologica, 2010
Background Aberrant activation of tyrosine kinases, caused by either mutation or gene fusion, is of major importance for the development of many hematologic malignancies, particularly myeloproliferative neoplasms.
Thomas Ernst, Andrew Chase, Katerina Zoi, Katherine Waghorn, Claire Hidalgo-Curtis, Joannah Score, Amy Jones, Francis Grand, Andreas Reiter, Andreas Hochhaus, Nicholas C.P. Cross   +10 more
doaj   +3 more sources

DNA Methylation in Ph-Negative Myeloproliferative Neoplasms: Prognostic Role and Therapeutic Implications [PDF]

Current Issues in Molecular Biology
Myeloproliferative neoplasms are clonal hematological neoplasms characterized by excessive proliferation of cells of erythroid, granulocytic, and megakaryocytic lineage.
Paola Barone, Adele Bottaro, Rossana Leanza, Fabio Stagno, Alessandro Allegra   +4 more
doaj   +2 more sources

Advances in Understanding and Management of Myeloproliferative Neoplasms

Ca-A Cancer Journal for Clinicians, 2009
Paola Guglielmelli
exaly   +2 more sources

A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms

Haematologica, 2014
Myeloproliferative neoplasms are a varied group of disorders that can have prolonged chronic phases, but eventually accelerate and can transform into a secondary acute myeloid leukemia that is ultimately fatal.
Joshua F. Zeidner, Judith E. Karp, Amanda L. Blackford, B. Douglas Smith, Ivana Gojo, Steven D. Gore, Mark J. Levis, Hetty E. Carraway, Jacqueline M. Greer, S. Percy Ivy, Keith W. Pratz, Michael A. McDevitt   +11 more
doaj   +3 more sources

Mutations, inflammation and phenotype of myeloproliferative neoplasms

Frontiers in Oncology, 2023
Knowledge on the myeloproliferative neoplasms (MPNs) – polycythemia vera (PV), essential thrombocythemia (ET), primary myelofibrosis (PMF) – has accumulated since the discovery of the JAK/STAT-activating mutations associated with MPNs: JAK2V617F ...
S. Hermouet
semanticscholar   +1 more source

Life histories of myeloproliferative neoplasms inferred from phylogenies

Nature, 2022
Mutations in cancer-associated genes drive tumour outgrowth, but our knowledge of the timing of driver mutations and subsequent clonal dynamics is limited1–3.
Williams N, Lee J, Mitchell E, Moore L, Baxter Ej, Hewinson J, Dawson Kj, Menzies A, Godfrey Al, Green Ar, Campbell Pj, Nangalia J   +11 more
semanticscholar   +1 more source

Clonal architecture evolution in Myeloproliferative Neoplasms: from a driver mutation to a complex heterogeneous mutational and phenotypic landscape

Leukemia, 2023
Myeloproliferative neoplasms are characterized by the acquisition at the hematopoietic stem cell level of driver mutations targeting the JAK/STAT pathway.
N. Maslah, L. Benajiba, S. Giraudier, J. Kiladjian, B. Cassinat   +4 more
semanticscholar   +1 more source

Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

The Journal of the National Comprehensive Cancer Network, 2022
The classic Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) consist of myelofibrosis, polycythemia vera, and essential thrombocythemia and are a heterogeneous group of clonal blood disorders characterized by an overproduction of blood
A. Gerds, J. Gotlib, H. Ali, P. Bose, A. Dunbar, Amro Elshoury, T. George, Krishna Gundabolu, E. Hexner, G. Hobbs, T. Jain, C. Jamieson, P. Kaesberg, A. Kuykendall, Y. Madanat, B. McMahon, S. Mohan, Kalyan Nadiminti, S. Oh, A. Pardanani, N. Podoltsev, Lindsay A. M. Rein, R. Salit, B. Stein, M. Talpaz, P. Vachhani, M. Wadleigh, S. Wall, Dawn C Ward, Mary Anne Bergman, Cindy Hochstetler   +30 more
semanticscholar   +1 more source

Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review

Cancers, 2023
Simple Summary Myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) are entities that have been quite difficult to define since their discovery.
D. Fontana, E. Elli, F. Pagni, R. Piazza
semanticscholar   +1 more source

International Consensus Classification of myeloid and lymphoid neoplasms: myeloproliferative neoplasms

Virchows Archiv, 2022
The recently published International Consensus Classification (ICC) of myeloid neoplasms summarized the results of an in-depth effort by pathologists, oncologists, and geneticists aimed to update the 2017 World Health Organization classification system ...
U. Gianelli, J. Thiele, A. Orazi, N. Gangat, A. Vannucchi, A. Tefferi, H. Kvasnicka   +6 more
semanticscholar   +1 more source